Last edition
News about "Boehringer Ingelheim"
Boehringer Ingelheim has initiated 3 phase 3 oncology trials, including DAREON-Lung-1 and DAREON-NEC-1, to evaluate obrixtamig as a DLL3 biomarker-guided treatment approach for hard-to-treat cancers.
Boehringer Ingelheim | 23/06/2026 | By News Bureau | 188
Boehringer Ingelheim Licenses Inflammation Antibody Program from Immunitas Therapeutics
Boehringer Ingelheim licenses a first-in-class antibody program from Immunitas Therapeutics to develop targeted therapies for chronic inflammatory diseases and expand its immunology pipeline.
Boehringer Ingelheim | 14/05/2026 | By News Bureau
The collaboration between Boehringer Ingelheim and BioNTech will evaluate a dual immuno-oncology approach in extensive-stage small cell lung cancer, aiming to improve outcomes in a disease with limited treatment options.
Boehringer Ingelheim | 11/04/2026 | By News Bureau | 120
CDR-Life Hits First Milestone in Boehringer Ingelheim Autoimmune Deal
CDR-Life has achieved its first milestone in its partnership with Boehringer Ingelheim, advancing an antibody-based programme targeting autoimmune diseases.
Boehringer Ingelheim | 24/03/2026 | By News Bureau | 116
Boehringer Ingelheim Appoints Meenal Gauri as Managing Director for India and South Asia
Boehringer Ingelheim has named Meenal Gauri as Managing Director India, effective January 12, 2026, overseeing operations across five South Asian markets and joining the company’s India board.
Boehringer Ingelheim | 25/02/2026 | By News Bureau | 217
Boehringer Ingelheim India and NIPER Raebareli Sign MoU to Boost Pharma Education and Research
The MoU between NIPER Raebareli and Boehringer Ingelheim establishes a framework to strengthen academic and research collaboration in areas such as pharmaceutical technologies, novel drug delivery systems, joint research initiatives, academic exchange and capability-building programmes.
Boehringer Ingelheim | 23/02/2026 | By News Bureau | 104
IQVIA and Boehringer Ingelheim Partner on Global Commercial Data Transformation
The long-term strategic collaboration aims to modernise Boehringer Ingelheim’s global commercial data foundation, enabling scalable, advanced analytics across therapeutic areas and regions using IQVIA’s industry-leading data model.
Boehringer Ingelheim | 31/01/2026 | By News Bureau | 318
Phase II data show apecotrep, a first-in-class oral TRPC6 inhibitor, significantly reduced proteinuria in patients with primary FSGS, supporting ongoing Phase III development.
Boehringer Ingelheim | 29/01/2026 | By News Bureau | 230
Boehringer and Simcere Partner on Dual-Target IBD Antibody
Boehringer Ingelheim has signed a licence and collaboration deal with Simcere to develop a novel TL1A/IL23p19 bispecific antibody for inflammatory bowel disease, gaining global rights outside greater China, with Simcere eligible for up to €1.058 billion in payments.
Boehringer Ingelheim | 29/01/2026 | By News Bureau | 128
Boehringer Ingelheim Begins Phase IIa Trial of BI 765423 in IPF
Boehringer Ingelheim has initiated a Phase IIa clinical trial of BI 765423, a novel IL-11–targeting monoclonal antibody, in patients with Idiopathic Pulmonary Fibrosis (IPF), advancing its efforts to develop new treatment options for progressive fibrotic lung diseases.
Boehringer Ingelheim | 15/01/2026 | By News Bureau | 831
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy